Follow Boston Scientific to never miss an important update.
Chief Executive Officer Michael Mahoney purchased about 9 million dollars worth of shares on the open market. Unlike the routine stock awards or scheduled sales that most executives use, an open-market purchase is a direct bet using the executive's own cash.
This move comes after the stock fell significantly following the company's latest financial results in late July. When a leader makes a purchase of this size during a rough patch, it often signals their confidence that the business remains healthy and that the market has overreacted to recent news.
Argus Research has lowered its rating on the company from buy to hold. This change comes as the stock trades at about $48, which is significantly lower than the average analyst target of $69.
While the company continues to grow its sales, a downgrade to hold often suggests an analyst sees fewer reasons for the stock price to rise in the near future. It may also reflect concerns about the recent cut to profit forecasts or the new restructuring plan.
Joseph Michael Fitzgerald, who leads the cardiology division, sold shares worth about $3 million. This was a discretionary sale, meaning it was not part of a pre-set automatic trading plan. While large sales can sometimes worry observers, executives often sell stock for personal financial planning or to diversify their own holdings. Because this sale represents a small fraction of the company's total value, it does not change the overall outlook for the business.
RBC Capital reduced its price target for the stock to $70, down from $85. Despite the lower target, the firm kept its outperform rating, which suggests they still expect the stock to do better than the average market return.
The adjustment follows the company's decision to lower its full-year profit forecast. Analysts often trim their targets when a company signals that earnings will be lower than previously thought, even if they remain positive on the long-term health of the business.
Source: RBC Capital
The company brought in $5.44 billion in sales last quarter, which was slightly better than the $5.38 billion analysts expected. Adjusted earnings per share came in at $0.86, also beating the $0.835 estimate. Overall sales grew about 7 percent compared to the same time last year.
However, the company lowered its profit forecast for the full year. Management noted that demand has softened for Watchman, a specialized device used to reduce stroke risk in heart patients. Because Watchman is a high-margin product, meaning it earns more profit per sale than many other tools, slower sales there have a larger impact on the company's bottom line. To address these pressures, the board approved a new restructuring plan aimed at cutting costs. While the quarterly results were solid, the lowered outlook suggests the company is facing a temporary slowdown in one of its most important growth areas.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Analysts recently lowered their price targets for Boston Scientific following the company's updated 2026 financial guidance. Most analysts still rate the stock a buy, with the average target of $67 suggesting 35% upside from today's price.
The company has a perfect record of beating analyst estimates for two years straight. Management consistently sets a bar they can clear, making their financial targets very reliable.
| Expectation | |
|---|---|
| EPS | $0.80 |
| Revenue | $5.26B |
Follow Boston Scientific to get the latest and most important updates.
Follow BSX